Investors Elated as Vertex Picks Two Top CF Triple Combos for Phase III Trials By Sam | January 31, 2018 Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy. Source: BioSpace Posted in BioPharma